In the News
LACRIFILL® Canalicular Gel is changing clinical practice and changing lives when it comes to dry eye treatment. Latest NewsNordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Continues Its Introduction of LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye, During American Academy of Ophthalmology (AAO) 2024
Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., launched LACRIFILL Canalicular Gel, a novel therapy for dry eye in the U.S. in April and will continue its introduction to leading ophthalmologists during AAO 2024. LACRIFILL Canalicular Gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system.
Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Announces the Launch of LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye
Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), to Present Data on LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye, at the American Society of Cataract and Refractive Surgery Annual Meeting
Come meet with us at these 2026 Meetings and Conferences
Vision Source Exchange
April 29–May 2
Nashville, TN
AAO
October 10–12
New Orleans, LA